Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related adverse effect and affects long-term quality of life.1 It has the potential to result in chemotherapy dose reductions and/or early discontinuation.The purpose of this study is to provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life.  READ MORE

Source: Journal of Clinical Oncology

Send this to a friend